How will the Critical Path Initiative help bring new treatments to patients?
With tools that can predict which product candidates do not hold promise early in the development process, product sponsors can redirect resources to more promising products. Early failures are efficient failures – they free up resources that would otherwise be invested in product candidates that will eventually fail. New Critical Path tools will help product sponsors devote those resources to new and better candidates, thus facilitating the availability of more new medical products for patients. In addition, modern evaluation tools will be more informative — we will learn more about products before they are approved. This will give doctors and patients the best available information about how to use the product to maximize its benefit and minimize side effects. In fact many of the tools being considered would help individualize therapy, by identifying who is likely to responds well to a treatment, and who should avoid it.
- What will the effect of these projects be on the medical product development process? How will the Critical Path Initiative help bring new treatments to patients?
- What new interventional treatments does Abington offer patients who present with critical brain events?
- How will the Critical Path Initiative help bring new treatments to patients?